Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASP7 | P55210 | 2/20 | 0.65 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.65 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.65 |
| ▸ | MAPT | P10636 | 2/20 | 0.65 |
| ▸ | BLM | P54132 | 2/20 | 0.65 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.65 |
| ▸ | MEN1 | O00255 | 1/20 | 0.65 |
| ▸ | RGS12 | O14924 | 1/20 | 0.65 |
| ▸ | LMNA | P02545 | 1/20 | 0.65 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.65 |
| ▸ | CASP1 | P29466 | 1/20 | 0.65 |
| ▸ | GNAI1 | P63096 | 1/20 | 0.65 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.65 |
| ▸ | USP2 | O75604 | 1/20 | 0.31 |
| ▸ | NOS1 | P29475 | 1/20 | 0.31 |
| ▸ | PAH | P00439 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | GLA | P06280 | 1/20 | 0.30 |
| ▸ | HPGD | P15428 | 1/20 | 0.30 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Sepiapterin SCHEMBL8288993 | 0.79 | HSD17B10 (1.00) | CASP7HSD17B10KDM4EMAPTBLM | |
| Sepiapterin SCHEMBL7943016 | 0.79 | HSD17B10 (1.00) | CASP7HSD17B10KDM4EMAPTBLM | |
| Sepiapterin SCHEMBL20374908 | 0.79 | HSD17B10 (1.00) | CASP7HSD17B10KDM4EMAPTBLM | |
| SCHEMBL31673801 | 0.77 | HSD17B10 (0.39) | CASP7HSD17B10KDM4EMAPTBLM | |
| SCHEMBL12559341 | 0.77 | HSD17B10 (0.39) | CASP7HSD17B10KDM4EMAPTBLM | |
| SCHEMBL258510 | 0.77 | HSD17B10 (0.39) | CASP7HSD17B10KDM4EMAPTBLM | |
| SCHEMBL22971947 | 0.77 | HSD17B10 (0.39) | CASP7HSD17B10KDM4EMAPTBLM | |
| SCHEMBL13721723 | 0.76 | KDM4E (0.38) | CASP7HSD17B10KDM4EMAPTBLM | |
| SCHEMBL7077081 | 0.74 | KDM4E (0.33) | CASP7HSD17B10KDM4EMAPTBLM | |
| SCHEMBL7362056 | 0.74 | KDM4E (0.33) | CASP7HSD17B10KDM4EMAPTBLM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1022 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4748370-A2 | COMPOSITIONS AND METHODS FOR INCREASING TETRAHYDROBIOPTERIN PLASMA EXPOSURE | PTC Therapeutics MP, Inc. (US) | 2026-05-27 | — | — | EP | claimed |
| US-12637465-B2 | Pharmaceutically acceptable salts of sepiapterin | PTC THERAPEUTICS MP, INC. (US) | 2026-05-26 | — | — | US | claimed |
| US-20260137729-A1 | RECOMBINANT BACTERIA EXPRESSING PHENYLALANINE AMMONIA LYASE, PHENYLALANINE TRANSPORTER AND L-AMINO ACID DEAMINASE FOR REDUCING HYPERPHENYLALANINEMIA | SYNLOGIC OPERATING COMPANY, INC. (US) | 2026-05-21 | — | — | US | claimed |
| US-20260091037-A1 | METHODS FOR INCREASING SEPIAPTERIN PLASMA EXPOSURE | PTC THERAPEUTICS MP INC (US) | 2026-04-02 | — | — | US | claimed |
| EP-3801534-B1 | TREATMENT OF PHENYLKETONURIA WITH SEPIAPTERIN | PTC THERAPEUTICS MP INC (US) | 2026-02-18 | — | — | EP | claimed |
| EP-4034122-B1 | METHODS FOR TREATING HYPERPHENYLALANINEMIA | PTC THERAPEUTICS MP INC (US) | 2025-08-13 | — | — | EP | claimed |
| US-20250230164-A1 | POLYMORPHS OF SEPIAPTERIN AND SALTS THEREOF | CENSA PHARMACEUTICALS INC. | 2025-07-17 | — | — | US | claimed |
| US-20250195529-A1 | COMPOSITIONS AND METHODS FOR INCREASING TETRAHYDROBIOPTERIN PLASMA EXPOSURE | PTC THERAPEUTICS MP, INC. | 2025-06-19 | — | — | US | claimed |
| US-20250195526-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING SEPIAPTERIN AND USES THEREOF | PTC THERAPEUTICS MP, INC. | 2025-06-19 | — | — | US | claimed |
| US-12329757-B2 | Methods for increasing sepiapterin plasma exposure | PTC THERAPEUTICS MP, INC. (US) | 2025-06-17 | — | — | US | claimed |
| EP-1530463-A1 | L-ARGININE CONTAINING PHARMACEUTICAL COMPOSITION | Vasopharm Biotech GmbH (DE) | 2005-05-18 | — | — | EP | claimed |
| WO-2005018620-A2 | USE OF NITRIC OXIDE SYNTHASE (NOS) COFACTOR FOR THE TREATMENT OF SEXUAL DYSFUNCTION | CELL CENTER COLOGNE GMBH (DE) | 2005-03-03 | — | — | WO | claimed |
| EP-1202736-A4 | NICOTINE IN THERAPEUTIC ANGIOGENESIS AND VASCULOGENESIS | UNIV LELAND STANFORD JUNIOR (US) | 2004-05-19 | — | — | EP | claimed |
| WO-2004017955-A1 | L-ARGININE CONTAINING PHARMACEUTICAL COMPOSITION | VASOPHARM BIOTECH GMBH (DE) | 2004-03-04 | — | — | WO | claimed |
| US-20020128294-A1 | Nicotine in therapeutic angiogenesis and vasculogenesis | BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY, THE | 2002-09-12 | — | — | US | claimed |
| US-6417205-B1 | Nicotine in therapeutic angiogenesis and vasculogenesis | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JR. UNIVERSITY | 2002-07-09 | — | — | US | claimed |
| EP-1202736-A1 | NICOTINE IN THERAPEUTIC ANGIOGENESIS AND VASCULOGENESIS | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2002-05-08 | — | — | EP | claimed |
| WO-2001008684-A1 | NICOTINE IN THERAPEUTIC ANGIOGENESIS AND VASCULOGENESIS | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2001-02-08 | — | — | WO | claimed |
| EP-0278040-B1 | USE OF PTERIDINES AND/OR PURINES OR OF A XANTHINEOXIDASE INHIBITOR FOR THE PREPARATION OF A MEDICAMENT FOR THE TREATMENT OF HEREDITARY DEGENERATIVE RETINAL DISEASES | PHARM-ALLERGAN GMBH (DE) | 1991-08-14 | — | — | EP | claimed |
| EP-0278040-A1 | Use of pteridines and/or purines or of a xanthineoxidase inhibitor for the preparation of a medicament for the treatment of hereditary degenerative retinal diseases | PHARM-ALLERGAN GMBH (DE) | 1988-08-17 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250230164-A1 | POLYMORPHS OF SEPIAPTERIN AND SALTS THEREOF | SPR, PAH, SORD | CASP7 1781/4885HSD17B10 251/4885KDM4E 1231/4885 |
| US-20260091037-A1 | METHODS FOR INCREASING SEPIAPTERIN PLASMA EXPOSURE | PAH, KMO, SHMT1 | CASP7 3851/4885HSD17B10 134/4885KDM4E 764/4885 |
| US-12329757-B2 | Methods for increasing sepiapterin plasma exposure | SPR, BHMT, BHMT2 | CASP7 2442/4885HSD17B10 624/4885KDM4E 414/4885 |
| US-20250195529-A1 | COMPOSITIONS AND METHODS FOR INCREASING TETRAHYDROBIOPTERIN PLASMA EXPOSURE | SPR, BHMT2, BHMT | CASP7 2309/4885HSD17B10 198/4885KDM4E 570/4885 |
| US-12637465-B2 | Pharmaceutically acceptable salts of sepiapterin | PAH, QDPR, SPR | CASP7 4080/4885HSD17B10 107/4885KDM4E 2101/4885 |
| US-20260137729-A1 | RECOMBINANT BACTERIA EXPRESSING PHENYLALANINE AMMONIA LYASE, PHENYLALANINE TRANSPORTER AND L-AMINO ACID DEAMINASE FOR REDUCING HYPERPHENYLALANINEMIA | ALAD, SLC1A5, ADA | CASP7 3374/4885HSD17B10 566/4885KDM4E 2028/4885 |
| US-20250195526-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING SEPIAPTERIN AND USES THEREOF | SPR, PCSK9, SLC6A7 | CASP7 2399/4885HSD17B10 229/4885KDM4E 2569/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.